Farmavita.Net is network for pharmaceutical licensing and regulatory affairs. http://www.farmavita.net 2010-03-10T04:53:25+01:00 http://www.farmavita.net http://www.farmavita.net/images/M_images/rss20.gif text/html 2010-02-25T12:06:56+01:00 http://www.farmavita.net http://www.farmavita.net/content/view/1389/120/ Lacerta BioCapital Lacerta BioCapital, a member of Farmavita.Net, invests in sound, stable companies in promising Life Science segments with attractive futures (e.g., sustained positive cash flow; value increase potential of at least 20% p.a.; growth potential either organically or through acquisition; etc.). Our target companies have a sound customer base with a well balanced product portfolio. We aim to have a total investment budget of approximately €300 million (including credit capital), to be invested in around 10-15 Life Science companies. Please contact us for introduction to Lacerta BioCapital. text/html 2010-02-12T16:48:31+01:00 http://www.farmavita.net http://www.farmavita.net/content/view/1368/57/ Our company offers probiotics in sachets or capsules in any concentration and containing any strains. We are very competitive in terms of prices and we are very flexible in terms of minimum batch. text/html 2010-02-04T10:36:30+01:00 http://www.farmavita.net http://www.farmavita.net/content/view/1338/84/ Diclofenac 1% Gel Member of Farmavita.Net team is looking for EU-CTD Dossier with supply for Diclofenac 1% Gel 50 mg for Italian Market. The Dossier should also contain full clinical studies. text/html 2010-01-14T10:36:44+01:00 http://www.farmavita.net http://www.farmavita.net/content/view/1316/84/ US Surgical Sutures Market: Surgical Procedures Growth to Drive Demand GlobalData's US Surgical Sutures Market: Surgical Procedures Growth to Drive Demand report is an essential source of data and analysis on the US surgical sutures market with complete coverage by categories. The report provides market landscape, competitive landscape and market trends information on two market categories - absorbable sutures and non absorbable sutures. The report identifies the key trends shaping and driving the dynamism in the US surgical sutures market. The report also provides insight on the prevalent competitive landscape and on the emerging players which are expected to bring significant shift in the market standing of the existing leaders. The report also provides valuable insight on the pipeline products within the US surgical sutures market. Claim 10% Discount for Farmavita.Net Members when purchasing this report! text/html 2010-01-11T21:59:54+01:00 http://www.farmavita.net http://www.farmavita.net/content/view/1315/84/ Seeking: Novel new sensations and materials for lip products A kiss may be just a kiss, but we're looking for unique materials to add to lip products for new lip sensations and experiences (such as cooling, warming, numbing, tingling and flavors), solutions that can impart prolonged sensate experiences, and solutions that can impart not-yet-known sensations. text/html 2009-12-15T23:21:58+01:00 http://www.farmavita.net http://www.farmavita.net/content/view/1303/57/ Development-stage pain products The Company seeks to divest its development-stage pain products MGX-001 (extended release morphine combined with an atypical stimulant) and MGX-002 (a follow-on opioid combined with an atypical stimulant). These products are expected to significantly reduce commonly-experienced side effects versus existing opiate therapies. text/html 2009-12-11T13:12:33+01:00 http://www.farmavita.net http://www.farmavita.net/content/view/1298/84/ Bacteria strains and fermentation technologies Farmavita.Net member is seeking bacteria strains and fermentation technologies to produce the following products Lycopene, Chlortetracycline and Acetylisovaleryltylosin. text/html 2009-12-03T09:51:58+01:00 http://www.farmavita.net http://www.farmavita.net/content/view/1289/84/ Mapping the Healthcare Landscape: Bringing pharmaceuticals into focus Courtesy of the patent cliff, the pharmaceutical industry is set for a dramatic slow down in revenue growth from 2011. Industry players are therefore looking to implement strategies which will cushion them against the anticipated revenue short-fall, with diversification away from pharmaceuticals into other healthcare sectors one avenue under consideration. Claim 10% Discount for Farmavita.Net Members when purchasing this report! text/html 2009-10-29T16:00:29+01:00 http://www.farmavita.net http://www.farmavita.net/content/view/1275/57/ Innovatve topical for Psoriasis We are interested in Co- development of an innovative topical formulation presented in a delivery system particularly targeted for treatment of Psoriasis and other dermatoses of hyperkeratotic nature. The formulation comprises of ingredients having anti inflammatory and a keratosolvent properties. The innovative formulation presented in a specially designed delivery system is patent potential and has superior clinical efficacy as compared to topical keratolytics such as Salicylic Acid, coal tar and synthetic retinoids. text/html 2009-10-14T13:23:16+01:00 http://www.farmavita.net http://www.farmavita.net/content/view/1270/84/ Pharma To Market provides global regulatory support services and outsourcing solutions to the pharmaceutical industry. Based in Australia, we are unique in that we offer regulatory and technical support for submissions in key global markets including Australia, New Zealand, USA, Europe, Canada, and South East Asia. Pharma To Market are licensed vendors of the Regulatory Solutions Suite (RSS) of software from ISI. We offer full implementation and maintenance services to companies in Australia and New Zealand for ISI's Regulatory Solutions Suite including eCTDXPress, ISIWriter, ISIToolBox and ISIPublisher. Pharma To Market also offer complete outsourcing solutions for eCTD and paper publishing. text/html 2009-09-28T11:54:42+01:00 http://www.farmavita.net http://www.farmavita.net/content/view/1259/84/ Biotech in the New EU Member States: Policy Recommendations The study carried-out on the development status and capacity of healthcare biotechnology in the new EU Member States and candidate countries shows a much contrasted picture of biotechnology development in this region. Each country has a different economic development strategy and a unique history and capacity in the life-science and healthcare sector which determines its path to development. Based on these observations, it would be unsuitable to propose general recommendations in a sort of unique formula to build or develop a healthy healthcare biotechnology sector. Donwnload free 14 pages report at our Download (http://www.farmavita.net/component/option,com_remository/Itemid,88/func,fileinfo/id,105/) Section. text/html 2009-09-28T10:40:23+01:00 http://www.farmavita.net http://www.farmavita.net/content/view/1258/84/ Biotech in the New EU Member States: an Emerging Sector This report is the first of its kind to try and understand the state of the biotechnology industry in the new Member States and candidate countries. As with any bottom-up work, it took a lot of effort and persistence to gather data on current and prospective developments in this area. Our goal was to strengthen the understanding of the European biotechnology scene and we believe that with the knowledge accumulated we have reached this goal. This report should enable policy makers and investors to make informed decisions about biotechnology support and development. The databases developed during this project will also provide better international visibility to the companies, which could lead to new cooperation or investment. Donwnload free 33 pages report at our Download (http://www.farmavita.net/component/option,com_remository/Itemid,88/func,fileinfo/id,104/) Section. text/html 2009-09-15T07:45:25+01:00 http://www.farmavita.net http://www.farmavita.net/content/view/1232/84/ I am looking for the competent technology offer for CEFUROXIME ACID. If any one is interested to fell cefuroxime acid technology can contact me. - Dr Anand Handa text/html 2009-09-01T23:02:57+01:00 http://www.farmavita.net http://www.farmavita.net/content/view/1223/84/ Open Innovation New R D Paradigm for Pharmaceutical Industry Over the next decade, the life sciences industries will be faced with sweeping demographic shifts, energy and environment threats, increasing globalization, mounting health care costs, the rise of emerging markets, and accelerating convergence between industry sectors. The life sciences industries are clearly poised for a period of massive shifts, and the most successful players in 2015 will be those whose strategies not only reflect these trends, but also adapt to them and take advantage of them. To do so, life sciences companies must first clearly understand the forces that are changing the industries, and the issues that they will need to overcome in order to be successful in 2015. text/html 2009-08-11T23:25:40+01:00 http://www.farmavita.net http://www.farmavita.net/content/view/1216/84/ @font-face { font-family: Cambria Math; } @font-face { font-family: Calibri; } @page Section1 P.MsoNormal { MARGIN: 0in 0in 0pt; FONT-FAMILY: "Calibri","sans-serif"; FONT-SIZE: 11pt; mso-style-unhide: no; mso-style-qformat: yes; mso-style-parent: ""; mso-pagination: widow-orphan; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: "Times New Roman" } LI.MsoNormal { MARGIN: 0in 0in 0pt; FONT-FAMILY: "Calibri","sans-serif"; FONT-SIZE: 11pt; mso-style-unhide: no; mso-style-qformat: yes; mso-style-parent: ""; mso-pagination: widow-orphan; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: "Times New Roman" } DIV.MsoNormal { MARGIN: 0in 0in 0pt; FONT-FAMILY: "Calibri","sans-serif"; FONT-SIZE: 11pt; mso-style-unhide: no; mso-style-qformat: yes; mso-style-parent: ""; mso-pagination: widow-orphan; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: "Times New Roman" } P.MsoListParagraph { MARGIN: 0in 0in 0pt 0.5in; FONT-FAMILY: "Calibri","sans-serif"; FONT-SIZE: 11pt; mso-style-unhide: no; mso-style-qformat: yes; mso-pagination: widow-orphan; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: "Times New Roman"; mso-style-priority: 34 } LI.MsoListParagraph { MARGIN: 0in 0in 0pt 0.5in; FONT-FAMILY: "Calibri","sans-serif"; FONT-SIZE: 11pt; mso-style-unhide: no; mso-style-qformat: yes; mso-pagination: widow-orphan; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: "Times New Roman"; mso-style-priority: 34 } DIV.MsoListParagraph { MARGIN: 0in 0in 0pt 0.5in; FONT-FAMILY: "Calibri","sans-serif"; FONT-SIZE: 11pt; mso-style-unhide: no; mso-style-qformat: yes; mso-pagination: widow-orphan; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: "Times New Roman"; mso-style-priority: 34 } .MsoChpDefault { mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: "Times New Roman"; mso-bidi-theme-font: minor-bidi; mso-style-type: export-only; mso-default-props: yes } .MsoPapDefault { LINE-HEIGHT: 115%; MARGIN-BOTTOM: 10pt; mso-style-type: export-only } DIV.Section1 { page: Section1 } OL { MARGIN-BOTTOM: 0in } UL { MARGIN-BOTTOM: 0in } Demand for contract manufacture of evacuated sterile parenteral product Client of Farmavita.Net is looking for contract manufacturer for the production evacuated, sterile glass bottles used for autohemotherapy with medical ozone.